Anti-Fibrinolytic Drugs - Southern Europe

Southern Europe

In Southern Europe, the Anti-Fibrinolytic Drugs market is anticipated to see a significant increase in revenue, with projections indicating a rise to US$0.62bn by 2024.
This growth is expected to continue at a compound annual growth rate (CAGR 2024-2028) of 3.81%, leading to a market volume of US$0.72bn by 2028.
In comparison to other countries worldwide, United States is projected to generate the highest revenue in this market, reaching a staggering amount of US$9,695.00m in 2024.
In Southern Europe, the demand for anti-fibrinolytic drugs is on the rise due to an aging population and increasing prevalence of cardiovascular diseases.

Key regions: India, Japan, France, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Fibrinolytic Drugs are a type of medication that helps to prevent the breakdown of blood clots, and are commonly used in surgeries and to treat bleeding disorders. In Southern Europe, the Anti-Fibrinolytic Drugs market has been showing some interesting trends and developments.

Customer preferences: Patients and healthcare providers in Southern Europe are increasingly turning towards Anti-Fibrinolytic Drugs as a way to manage bleeding disorders and to prevent excessive bleeding during surgeries. This is due to the effectiveness of these drugs in preventing blood clots from breaking down, which can lead to prolonged bleeding and other complications.

Trends in the market: Spain, Italy, and Greece are the three largest markets for Anti-Fibrinolytic Drugs in Southern Europe. In Spain, the market is being driven by an aging population and an increase in the number of surgeries being performed. In Italy, the market is being driven by an increase in the number of patients being diagnosed with bleeding disorders. In Greece, the market is being driven by an increase in the number of patients being treated for trauma-related injuries.

Local special circumstances: In Spain, the use of Anti-Fibrinolytic Drugs is becoming more widespread due to the country's aging population. As people get older, they are more likely to require surgery, and Anti-Fibrinolytic Drugs are an effective way to prevent excessive bleeding during these procedures.In Italy, the use of Anti-Fibrinolytic Drugs is being driven by an increase in the number of patients being diagnosed with bleeding disorders. This is due to improved diagnosis and screening methods, as well as an increase in awareness of these conditions.In Greece, the use of Anti-Fibrinolytic Drugs is being driven by an increase in the number of patients being treated for trauma-related injuries. Greece has seen a rise in the number of accidents and injuries in recent years, and Anti-Fibrinolytic Drugs are an effective way to prevent excessive bleeding in these patients.

Underlying macroeconomic factors: The Anti-Fibrinolytic Drugs market in Southern Europe is also being influenced by broader macroeconomic factors. For example, the economic crisis in Greece has led to a decrease in healthcare spending, which has had an impact on the availability and affordability of these drugs. In contrast, the healthcare systems in Spain and Italy are more robust, which has allowed for greater access to Anti-Fibrinolytic Drugs.Overall, the Anti-Fibrinolytic Drugs market in Southern Europe is showing steady growth, driven by an increase in the number of surgeries being performed, an aging population, and an increase in the number of patients being diagnosed with bleeding disorders and trauma-related injuries. However, the market is also being influenced by broader macroeconomic factors, which are impacting the availability and affordability of these drugs in some countries.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.